Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1524657 | 0.96 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL984941 | 0.96 | — | — | |
| SCHEMBL1173999 | 0.96 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL6101790 | 0.96 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL10494046 | 0.96 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL11001515 | 0.96 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL22033837 | 0.96 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL22033682 | 0.96 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL3883393 | 0.92 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL9004375 | 0.92 | ALDH1A1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024926-A1 | A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-01-27 | — | — | US | claimed |
| CN-113717170-A | Estrogen receptor modulators | 里科瑞尔姆IP控股有限责任公司 | 2021-11-30 | — | — | CN | claimed |
| CN-112745316-A | Estrogen receptor modulators | 里科瑞尔姆IP控股有限责任公司 | 2021-05-04 | — | — | CN | claimed |
| CN-112679495-A | Estrogen receptor modulators | 里科瑞尔姆IP控股有限责任公司 | 2021-04-20 | — | — | CN | claimed |
| WO-2020118139-A1 | A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-11 | — | — | WO | claimed |
| US-20080171662-A1 | Aminocarbonyl-Substituted Thiensulfonylamino(Thio)Carbonyl-Triazolin(Ethi)Ones, Processes For Their Preparation And Their Use | BAYER CROPSCIENCE AG (DE) | 2008-07-17 | — | — | US | claimed |
| WO-2007118474-A2 | METHOD FOR THE PRODUCTION OF HYDROGEN-RICH SILANES, AND NOVEL CHEMICAL COMPOUNDS | TECHNISCHE UNIVERSITÄT BERGAKADEMIE FREIBERG (DE) | 2007-10-25 | — | — | WO | claimed |
| EP-1776012-A1 | AMINOCARBONYL-SUBSTITUTED THIENSULPHONYLAMINO (THIO) CARBONYLTRIAZOLIN (THI) ONES METHODS FOR PRODUCTION AND USE THEREOF | Bayer CropScience Aktiengesellschaft (DE) | 2007-04-25 | — | — | EP | claimed |
| WO-2006012981-A1 | AMINOCARBONYL-SUBSTITUTED THIENYLSULPHONYLUREAS | BAYER CROPSCIENCE AG (DE) | 2006-02-09 | — | — | WO | claimed |
| WO-2006012983-A1 | AMINOCARBONYL-SUBSTITUTED THIENSULPHONYLAMINO (THIO) CARBONYLTRIAZOLIN (THI) ONES METHODS FOR PRODUCTION AND USE THEREOF | BAYER CROPSCIENCE AG (DE) | 2006-02-09 | — | — | WO | claimed |
| EP-1623987-A1 | Fused pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and pyrido[3',2':4,5]furo[3,2-d]pyrimidines | Curacyte Discovery GmbH (DE) | 2006-02-08 | — | — | EP | claimed |
| EP-1619196-A1 | Substituted Pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and Pyrido[3',2':4,5]furo[3,2-d]-pyrimidines for use as inhibitors of PDA-4 and/or TNF-alpha release | Curacyte Discovery GmbH (DE) | 2006-01-25 | — | — | EP | claimed |
| EP-1619197-A1 | Substituted Pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1H,3H)diones and -4(3H)ones as well as Pyrido[3',2':4,5]furo[3,2-d]-pyrimidin-2,4(1H,3H)diones und -4(3H)ones as inhibitors of TNF-alpha release | Curacyte Discovery GmbH (DE) | 2006-01-25 | — | — | EP | claimed |
| EP-1104422-A1 | PHENYL XANTHINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-06-06 | — | — | EP | claimed |
| WO-2000009507-A1 | PHENYL YANTHINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-02-24 | — | — | WO | claimed |
| US-20230242785-A1 | PHOTOCURABLE COMPOSITION, THREE-DIMENSIONAL MODELING PRODUCT, AND DENTAL PRODUCT | MITSUI CHEMICALS, INC. (JP) | 2023-08-03 | — | — | US | disclosed |
| EP-4163308-A1 | PHOTOCURABLE COMPOSITION, THREE-DIMENSIONAL SHAPED ARTICLE, AND DENTAL PRODUCT | Mitsui Chemicals, Inc. (JP) | 2023-04-12 | — | — | EP | disclosed |
| US-5217856-A | TETRAAZAPORPHIN, PROCESS FOR PRODUCING THE SAME, AS WELL AS OPTICAL RECORDING MEDIA USING THE SAME AND PRODUCTION PROCESSES THEREOF | HITACHI CHEMICAL CO., LTD. (JP) | 1993-06-08 | — | — | US | disclosed |
| EP-0366440-A2 | Naphthalocyanine derivatives, production thereof, optical recording medium using the same, and production thereof | Hitachi Chemical Co., Ltd. (JP) | 1990-05-02 | — | — | EP | disclosed |
| EP-0344891-A2 | Tetraazaporphin, process for producing the same, as well as optical recording media using the same and production processes thereof | Hitachi Chemical Co., Ltd. (JP) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171662-A1 | Aminocarbonyl-Substituted Thiensulfonylamino(Thio)Carbonyl-Triazolin(Ethi)Ones, Processes For Their Preparation And Their Use | TST, SULT1E1, CBR3 | ALDH1A1 996/4885THRB 230/4885MEN1 3811/4885 |
| US-20220024926-A1 | A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF | ADORA1, ADORA2A, ADORA2B | ALDH1A1 231/4885THRB 144/4885MEN1 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.